Article

AHA Statement Offers Advice on Treating Deep Vein Thrombosis

The AHA is encouraging doctors to consider therapies in addition to blood thinners to treat certain patients with potentially dangerous DVT.

Doctors are encouraged to consider therapies in addition to blood thinners to treat certain patients with potentially dangerous deep vein thrombosis (DVT), according to a new scientific statement from the American Heart Association. The statement is published online in Circulation: Journal of the American Heart Association.

More than 250,000 people in the United States are hospitalized with DVT each year. Previously, there has been limited guidance for physicians on some of the more serious conditions caused by DVT.

The statement offers advice for cardiologists and a range of other physicians who treat the disorder. Guidance is provided for identifying and treating people with massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension.

“It is important for doctors to be able to identify the severity of these disorders and to select who might be eligible for more invasive therapies, such as clot-busting drugs, catheter-based treatments, or surgery,” said M. Sean McMurtry, MD, co-chair of the statement writing group. “Venous thromboembolism is very common and frequently a complication of other ailments. While most patients need blood thinners only, patients with more severe forms of venous thromboembolism may benefit from more aggressive treatments,” he said in a news release.

The statement outlines multiple treatment options including the use of fibrinolytic drugs, catheter-based interventions, treatment with surgery to remove the blood clots, and use of filters that prevent clots from traveling in the veins from the legs to the lungs, where they can cause strain on the heart. Additional guidance for treating pediatric patients is also included.

HCPLive wants to know:

Do you agree with the AHA's new scientific statement?Do you see it changing how you practice medicine?Do you agree that patients with more severe forms of venous thromboembolism may benefit from more aggressive treatments?Leave a comment below!

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orly Vardeny, PharmD: Finerenone for Heart Failure with EF >40% in FINEARTS-HF | Image Credit: JACC Journals
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Matthew Weir, MD: Prioritizing Cardiovascular Risk in Chronic Kidney Disease | Image Credit: University of Maryland
Erin Michos, MD: HFpEF in Women and Sex-Specific Therapeutic Approaches | Image Credit: Johns Hopkins
© 2024 MJH Life Sciences

All rights reserved.